Absorption, distribution, metabolism, and excretion of US Food and Drug Administration–Approved antisense oligonucleotide drugs
JM Migliorati, S Liu, A Liu, A Gogate, S Nair… - Drug Metabolism and …, 2022 - ASPET
Absorption, distribution, metabolism, and excretion (ADME) are the key biologic processes
for determination of a drug's pharmacokinetic parameters, which have direct impacts on …
for determination of a drug's pharmacokinetic parameters, which have direct impacts on …
Targeting the Liver with Nucleic Acid Therapeutics for the Treatment of Systemic Diseases of Liver Origin
A Gogate, J Belcourt, M Shah, AZ Wang… - Pharmacological …, 2024 - ASPET
Systemic diseases of liver origin (SDLO) are complex diseases in multiple organ systems,
such as cardiovascular, musculoskeletal, endocrine, renal, respiratory, and sensory organ …
such as cardiovascular, musculoskeletal, endocrine, renal, respiratory, and sensory organ …
[HTML][HTML] Correlation between pathologic complete response, event-free survival/disease-free survival and overall survival in neoadjuvant and/or adjuvant HR+/HER2 …
A Gogate, S Ranjan, A Kumar, H Bhandari… - Frontiers in …, 2023 - frontiersin.org
Purpose The study's purpose was to evaluate the correlation between overall survival (OS)
and its potential surrogate endpoints: pathologic complete response (pCR) and event-free …
and its potential surrogate endpoints: pathologic complete response (pCR) and event-free …
Projecting the prevalence and costs of metastatic breast cancer from 2015 through 2030
A Gogate, SB Wheeler, KE Reeder-Hayes… - JNCI Cancer …, 2021 - academic.oup.com
Background This study projected the number of metastatic breast cancer (mBC) cases and
costs (medical and productivity) attributable to mBC through 2030 among 3 age groups …
costs (medical and productivity) attributable to mBC through 2030 among 3 age groups …
Medical costs associated with metastatic breast cancer in younger, midlife, and older women
JG Trogdon, CD Baggett, A Gogate… - Breast cancer research …, 2020 - Springer
Purpose We estimated average medical costs due to metastatic breast cancer (mBC) among
younger (aged 18–44), midlife (aged 45–64), and older women (aged 65 and older) by …
younger (aged 18–44), midlife (aged 45–64), and older women (aged 65 and older) by …
Treatment patterns and outcomes for patients with newly diagnosed glioblastoma multiforme: a retrospective cohort study
S Annavarapu, A Gogate, T Pham, K Davies… - CNS …, 2021 - Future Medicine
Aim: Investigate real-world outcomes and healthcare utilization of patients with glioblastoma
multiforme (GBM) related to O6-methylguanine DNA methyltransferase (MGMT) promoter …
multiforme (GBM) related to O6-methylguanine DNA methyltransferase (MGMT) promoter …
[HTML][HTML] Cost-effectiveness of pharmacologic treatment options for women with endocrine-refractory or triple-negative metastatic breast cancer
SB Wheeler, J Rotter, A Gogate… - Journal of Clinical …, 2023 - ncbi.nlm.nih.gov
PURPOSE Treatments for endocrine-refractory or triple-negative metastatic breast cancer
(mBC) are modestly effective at prolonging life and improving quality of life but can be …
(mBC) are modestly effective at prolonging life and improving quality of life but can be …
An updated systematic review of the cost-effectiveness of therapies for metastatic breast cancer
A Gogate, JS Rotter, JG Trogdon, K Meng… - Breast cancer research …, 2019 - Springer
Purpose The goal of this systematic review is to provide an update to the review by Pouwels
et al. by conducting a systematic review and an assessment of the reporting quality of the …
et al. by conducting a systematic review and an assessment of the reporting quality of the …
Economic analysis of neoadjuvant chemotherapy versus primary debulking surgery for advanced epithelial ovarian cancer using an aggressive surgical paradigm
AL Cole, EL Barber, A Gogate, AQ Tran… - International Journal of …, 2018 - ijgc.bmj.com
Objectives Neoadjuvant chemotherapy (NACT) versus primary debulking surgery (PDS) for
advanced epithelial ovarian cancer (AEOC) remains controversial in the United States …
advanced epithelial ovarian cancer (AEOC) remains controversial in the United States …
[HTML][HTML] Phase 4 Multinational Multicenter Retrospective and Prospective Real-World Study of Nivolumab in Recurrent and Metastatic Squamous Cell Carcinoma of …
Simple Summary In 2020, there were 880,000 new cases and 440,000 deaths attributed to
head and neck cancer worldwide. Nivolumab was approved in 2016 in the United States …
head and neck cancer worldwide. Nivolumab was approved in 2016 in the United States …